Journal Article

Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer

Steven A. Belinsky

in Carcinogenesis

Volume 26, issue 9, pages 1481-1487
Published in print September 2005 | ISSN: 0143-3334
Published online January 2005 | e-ISSN: 1460-2180 | DOI:
Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer

More Like This

Show all results sharing this subject:

  • Clinical Cytogenetics and Molecular Genetics


Show Summary Details


Transcriptional silencing by CpG island hypermethylation has become a critical component in the initiation and progression of lung cancer. The ability of pharmacologic agents to reverse promoter hypermethylation also makes it an attractive target to pursue for prevention of lung cancer. Animal models, together with studies in humans have fostered significant advances in elucidating the role of gene-specific methylation in cancer initiation and progression, the modulation of promoter methylation by carcinogen exposure and the ability to block tumor development by preventing epigenetically mediated gene silencing. These advances represent the beginning of efforts to develop a progression model for lung cancer that should aid efforts for early detection and gene targeting for therapy, and the development of preventive interventions that reverse epigenetic-mediated gene silencing.

Keywords: CDKN2A, p16; DAP-K, death associated protein kinase; MGMT, O6-methylguainine-DNA methyltransferase; RAR-β, retinoic acid receptor β; ER, estrogen receptor α; SCC, squamous cell carcinoma; NNK, 4-methylnitrosamino-1-(3-pyridyl)-1-butanone; DNMT, cytosine DNA-methyltransferase; DAC, 5-aza-2′-deoxyazacytidine

Journal Article.  5304 words.  Illustrated.

Subjects: Clinical Cytogenetics and Molecular Genetics

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.